Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
Ogan
K
K
Department of Urology, George Washington University, Fairfax Hospital, Virginia, USA.
Berger
M
M
Ball
R
R
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D000236:Adenoma / Q000473:pathology* / Q000601:surgery; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007016:Hypophysectomy; D016729:Leuprolide / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000473:pathology*; D010911:Pituitary Neoplasms / Q000473:pathology* / Q000601:surgery; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D013739:Testosterone / Q000097:blood; D017211:Treatment Failure
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D013739:Testosterone; D007986:Luteinizing Hormone; D017430:Prostate-Specific Antigen; D016729:Leuprolide